Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monica A Slavin

Showing results (81-90 of 281) with videos related to

Pageof 29
Sort By:
British Journal of Haematology|December 24, 2005
Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*Karin A Thursky, Leon J Worth, John F Seymour, et al.
European Journal of Cancer (Oxford, England : 1990)|September 5, 2016
Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysisBenjamin W Teh, Simon J Harrison, Leon J Worth, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 10, 2014
Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer HospitalBenjamin W Teh, Leon J Worth, Simon J Harrison, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 30, 2019
Beta-Lactam and Sulfonamide Allergy Testing Should Be a Standard of Care in Immunocompromised HostsJason A Trubiano, Monica A Slavin, Karin A Thursky, et al.
Mycoses|September 5, 2020
Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi-centre cohort studyChhay Lim, Priyadarshini Sinha, Simon J Harrison, et al.
BMJ Open|September 12, 2024
Protocol for a clinically annotated biorepository of samples from Australian immune-compromised patients to investigate the host-microbiome interactionOlivia C Smibert, Jason A Trubiano, Jason C Kwong, et al.
Open Forum Infectious Diseases|January 12, 2026
Differences in Clinical Outcomes Among Patients With Mold FungemiaAdam G Stewart, Kevin B Laupland, Felicity Edwards, et al.
The Lancet. Oncology|February 3, 2020
Levofloxacin prophylaxis in patients with myelomaBenjamin W Teh, Simon J Harrison, Leon J Worth, et al.
Mycoses|July 8, 2025
Epidemiology, Significance and Clinical Outcomes of Bloodstream Infections Caused by Non-Candida and Non-Cryptococcus YeastsAdam G Stewart, Kevin B Laupland, Felicity Edwards, et al.
The Medical Journal of Australia|June 15, 2018
How antibiotic allergy labels may be harming our most vulnerable patientsJason A Trubiano, M Lindsay Grayson, Karin A Thursky, et al.
Pageof 29

Showing results (81-90 of 281) with videos related to

Sort By:
Pageof 29
British Journal of Haematology|December 24, 2005
Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*Karin A Thursky, Leon J Worth, John F Seymour, et al.
European Journal of Cancer (Oxford, England : 1990)|September 5, 2016
Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysisBenjamin W Teh, Simon J Harrison, Leon J Worth, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 10, 2014
Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer HospitalBenjamin W Teh, Leon J Worth, Simon J Harrison, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 30, 2019
Beta-Lactam and Sulfonamide Allergy Testing Should Be a Standard of Care in Immunocompromised HostsJason A Trubiano, Monica A Slavin, Karin A Thursky, et al.
Mycoses|September 5, 2020
Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi-centre cohort studyChhay Lim, Priyadarshini Sinha, Simon J Harrison, et al.
BMJ Open|September 12, 2024
Protocol for a clinically annotated biorepository of samples from Australian immune-compromised patients to investigate the host-microbiome interactionOlivia C Smibert, Jason A Trubiano, Jason C Kwong, et al.
Open Forum Infectious Diseases|January 12, 2026
Differences in Clinical Outcomes Among Patients With Mold FungemiaAdam G Stewart, Kevin B Laupland, Felicity Edwards, et al.
The Lancet. Oncology|February 3, 2020
Levofloxacin prophylaxis in patients with myelomaBenjamin W Teh, Simon J Harrison, Leon J Worth, et al.
Mycoses|July 8, 2025
Epidemiology, Significance and Clinical Outcomes of Bloodstream Infections Caused by Non-Candida and Non-Cryptococcus YeastsAdam G Stewart, Kevin B Laupland, Felicity Edwards, et al.
The Medical Journal of Australia|June 15, 2018
How antibiotic allergy labels may be harming our most vulnerable patientsJason A Trubiano, M Lindsay Grayson, Karin A Thursky, et al.
Pageof 29